Search

Displaying results 561 - 570 of 7687 in total
  1. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to

  2. Drug

    Iobenguane sulfate I-123

    go.drugbank.com/drugs/DB09546
    Approved

    Iobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].

  3. Drug

    Loteprednol etabonate

    go.drugbank.com/drugs/DB14596
    Approved

    As a nasal spray, it can be used for the treatment and management of seasonal allergic rhinitis. … Most prescription LE products, however, tend to be indicated for the treatment of post-operative inflammation and pain following ocular surgery [FDA Label].

  4. Drug

    Thiothixene

    go.drugbank.com/drugs/DB01623
    Approved

    A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics.

    Categories: Dopamine D2 Receptor Antagonists
  5. Drug

    Ofloxacin

    go.drugbank.com/drugs/DB01165
    ApprovedInvestigational

    A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

    Products: FLOXSTAT (R)TABLETAS DE 200 MG
  6. Drug

    Lumateperone

    go.drugbank.com/drugs/DB06077
    ApprovedInvestigational

    [A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. … [A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.

    Categories: Dopamine D2 Receptor Agonists
  7. Drug

    Crotalus adamanteus antivenin

    go.drugbank.com/drugs/DB13893
    Approved

    It is intravenously administered to limit systemic toxicity [FDA label].

  8. Drug

    Brexanolone

    go.drugbank.com/drugs/DB11859
    ApprovedInvestigational

    As of March 2019, brexanolone - developed and made available commercially by Sage Therapeutics Inc. as the brand name product Zulresso - is the first drug to have ever been approved by the US FDA specifically … susceptible to PPD whereas many commonly used anti-depressive medications elicit actions that may modulate the presence and activity of substances like serotonin, norepinephrine, and/or monoamine oxidase but do

  9. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    As of December 11, 2017 the FDA approved Ferrer Internacional S.A.'

  10. Drug

    Terbinafine

    go.drugbank.com/drugs/DB00857
    ApprovedInvestigationalVet approved

    [A1279,A1281,L9068] Terbinafine hydrochloride was granted FDA approval on 30 December 1992.[L9064] … [A1279] Like other allylamines, terbinafine inhibits ergosterol synthesis by inhibiting the fungal squalene monooxygenase (also called squalene epoxidase), an enzyme that is part of the fungal cell wall

    Products: LAMISIL 1 SOLUCION FORMADORA DE PELICULA, Nu-terbinafine